Abiopharma

AXOGEN, INC. (AXGN)

Symbol	AXGN
Name	AXOGEN, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Electromedical & Electrotherapeutic Apparatus
Address	13631 PROGRESS BOULEVARD,SUITE 400, ALACHUA, Florida, 32615, United States
Telephone	+1 386 462-6800
Fax	—
Email	—
Website	https://www.axogeninc.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0000805928
Description	Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain. Additional info from NASDAQ: Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about helping to restore peripheral nerve function and quality of life to patients with physical damage or transection to peripheral nerves by providing innovative, clinically proven, and economically effective repair solutions for surgeons and health care providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve, or the inability to properly reconnect peripheral nerves, can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

2026-09-10 17:55

New Form 8-K/A - Axogen, Inc. Filed: 2026-09-10 AccNo: 0001628280-26-061393 Size: 3 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

2026-09-10 10:02

(75% Positive) AXOGEN, INC. (AXGN) Announces Business Combination

2026-09-10 10:01

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

2026-09-10 10:01

Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock

2026-09-10 10:00

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

2026-09-10 10:00

Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies

2026-09-04 20:08

Director TYNDALL JOSEPH A. 🔴 sold 3.5K shares of Axogen, Inc. (AXGN) at $49.70 Transaction Date: Sep 02, 2026 | Filing ID: 000101

2026-09-02 20:32

📋 JOSEPH A TYNDALL (Director) plans to sell 4K shares of Axogen, Inc. (at $49.88 each, total $175K) Filed: Sep 02, 2026 | ID: 009025

2026-09-01 11:00

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

2026-09-01 11:00

Axogen, Inc. to Participate in the 24th Annual Morgan Stanley Global Healthcare Conference

No clinical trials found for this company.

No clinical products found for this company.